Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 1:9:1170.
doi: 10.3389/fphar.2018.01170. eCollection 2018.

Di'ao Xinxuekang Capsule, a Chinese Medicinal Product, Decreases Serum Lipids Levels in High-Fat Diet-Fed ApoE-/- Mice by Downregulating PCSK9

Liping Qu  1 , Didi Li  1 , Xiaoping Gao  1 , Yongwei Li  2 , Jianming Wu  3 , Wenjun Zou  1
Affiliations
Free PMC article

Di'ao Xinxuekang Capsule, a Chinese Medicinal Product, Decreases Serum Lipids Levels in High-Fat Diet-Fed ApoE-/- Mice by Downregulating PCSK9

Liping Qu et al. Front Pharmacol. .
Free PMC article

Abstract

Numerous risk factors are responsible for the development of atherosclerosis, for which an increased serum level of low-density lipoprotein cholesterol (LDL-C) is a driving force. By binding to the low-density lipoprotein cholesterol receptor (LDLR) and inducing LDLR degradation, proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in cholesterol homeostasis regulation. The inducement of PCSK9 expression is also an important reason for statin intolerance. The Di'ao Xinxuekang (DXXK) capsule extracted from Dioscorea nipponica Makino is a well-known traditional Chinese herbal medicinal product used in atherosclerotic cardiovascular disease. Although DXXK has been widely used in atherosclerotic cardiovascular treatment for nearly 30 years, studies on the potential mechanisms of the lipid-lowering effect are very limited. The purpose of the present study was to demonstrate the possible involvement of the PCSK9/LDLR signaling pathway in the lipid-lowering and antiatherosclerotic effect of DXXK in high-fat diet-fed ApoE-/- mice. The results showed that DXXK treatment alleviated hyperlipidemia, fat accumulation, and atherosclerosis formation in ApoE-/- mice. Furthermore, changes in the expression of PCSK9 mRNA in liver tissue and the circulating PCSK9 level in ApoE-/- mice were both reversed after DXXK treatment, and upregulation of LDLR in the liver was also detected in the protein level in DXXK-treated mice. Our study is the first to show that DXXK could alleviate lipid disorder and ameliorate atherosclerosis with downregulation of the PCSK9 in high-fat diet-fed ApoE-/- mice, suggesting that DXXK may be a potential novel therapeutic treatment and may support statin action in the treatment of atherosclerosis.

Keywords: ApoE–/– mice; Di’ao Xinxuekang; LDL-C; LDLR; PCSK9.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Analysis of protodioscin (1), pseudoprodioscin (2), and dioscin (3) concentrations in DXXK.
FIGURE 2
FIGURE 2
Effect of DXXK on serum lipid levels in ApoE–/– mice fed a high fat diet. The DXXK treatment decreased the levels of serum TC (A), TG (B), and LDL-C (D) and increased the serum HDL-C (C). ∗ Indicates a significant difference (P < 0.05) and ∗∗ (P < 0.01) versus model group. ATO, atorvastatin.
FIGURE 3
FIGURE 3
Effect of DXXK on the lipid accumulation in aortas of ApoE–/– mice fed a high-fat diet. Representative photomicrographs Oil red O-stained fatty streaks in the aorta (A) (Magnification: ×400). Quantitative analysis of atherosclerotic lesions in the aorta section (B). ∗ Indicates a significant difference (P < 0.05) and ∗∗ (P < 0.01) versus model group. ATO, atorvastatin.
FIGURE 4
FIGURE 4
Effect of DXXK on the lipid accumulation in livers of ApoE–/– mice fed a high-fat diet. Representative photomicrographs of oil red O-stained fatty streaks in the liver tissue (A) (Magnification: ×400). Quantitative analysis of atherosclerotic lesions in the liver section (B). ∗ Indicates a significant difference (P < 0.05) and ∗∗ (P < 0.01) versus model group. ATO, atorvastatin.
FIGURE 5
FIGURE 5
Effect of DXXK on the mRNA expression of PCSK9 (A) and LDLR (B) in ApoE–/– mice fed a high-fat diet. ∗ Indicates a significant difference (P < 0.05) and ∗∗ (P < 0.01) versus model group. ATO, atorvastatin.
FIGURE 6
FIGURE 6
Effect of DXXK on serum PCSK9 level (A) and protein expression of liver LDLR (B) in ApoE–/– mice fed a high-fat diet. ∗ Indicates a significant difference (P < 0.05) and ∗∗ (P < 0.01) versus model group. ATO, atorvastatin.
FIGURE 7
FIGURE 7
The DXXK decreases serum LDL-C level through PCSK9/LDLR pathway.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Careskey H. E., Davis R. A., Alborn W. E., Troutt J. S., Cao G., Konrad R. J. (2008). Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J. Lipid Res. 49 394–398. 10.1194/jlr.M700437-JLR200 - DOI - PubMed
    1. Chen S. X., Chen M. F., Zheng X. J., Chang P. L. (1995). Effects of Di’ao Xinxuekang on vascular function and microcirculation of nail fold in patients with coronary artery disease. Zhongguo Xin Yao Yu Lin Chuang za Zhi 14 349–352.
    1. Chinese Pharmacopoeia Commission (2015). Pharmacopoeia of the People’s Republic of China. Beijing: Science Press, 820–821.
    1. Cohen J. C., Boerwinkle E., Mosley T. H., Jr., Hobbs H. H. (2006). Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354 1264–1272. 10.1056/NEJMoa054013 - DOI - PubMed
    1. Dixon D. L., Trankle C., Buckley L., Parod E., Carbone S., Van Tassell B. W., et al. (2016). A review of PCSK9 inhibition and its effects beyond LDL receptors. J. Clin. Lipidol. 10 1073–1080. 10.1016/j.jacl.2016.07.004 - DOI - PubMed